Initiation of acetylcholinesterase inhibitors and complications of chronic airways disorders in elderly patients

Drug Safety

Volumn 29, Issue 11, 2006, Pages 1077-1085

  Thacker, Evan L ^a,b   Schneeweiss, Sebastian ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMINOPHYLLINE; BECLOMETASONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUDESONIDE; CHOLINE THEOPHYLLINATE; CHOLINESTERASE INHIBITOR; DEXAMETHASONE; DIPROPHYLLINE; DONEPEZIL; FLUNISOLIDE; FLUTICASONE PROPIONATE; FORMOTEROL; GALANTAMINE; IPRATROPIUM BROMIDE; ISOETARINE; ISOPRENALINE; LEVALBUTEROL; MONTELUKAST; ORCIPRENALINE; PIRBUTEROL; RIVASTIGMINE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; ZAFIRLUKAST; ZILEUTON;

AGED; ARTICLE; CHRONIC RESPIRATORY TRACT DISEASE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CONTRAINDICATION; ELDERLY CARE; EMERGENCY CARE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; CHRONIC DISEASE; CROSS-OVER STUDIES; FEMALE; GALANTAMINE; HUMANS; INDANS; LOGISTIC MODELS; MALE; PHENYLCARBAMATES; PIPERIDINES; RESPIRATORY TRACT DISEASES;

EID: 33845477666     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200629110-00007     Document Type: Article

References (42)

1. McCormick WC, Kukull WA, van Belle G, et al. Symptom patterns and comorbidity in the early stages of Alzheimer's disease. J Am Geriatr Soc 1994 May; 42 (5): 517-21
2. National Center for Health Statistics. National Nursing Home Survey public-use data files 1999 [online]. Available from URL: http://www.cdc.gov/ nchs/about/major/nnhsd/nnhsd.htm [Accessed 2005 Apr 30]
3. Doraiswamy PM, Leon J, Cummings JL, et al. Prevalence and impact of medical comorbidity in Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2002 Mar; 57 (3): M173-7
4. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003 Aug; 60 (8): 1119-22
5. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. MMWR Surveill Summ 2002 Aug; 51 (6): 1-16
6. Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma: United States, 1980-1999. MMWR Surveill Summ 2002 Mar; 51 (1): 1-13
7. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000 May; 117 (5 Suppl. 2): 380S-5S
8. Kreit JW, Rogers RM. Chronic obstructive pulmonary disease and emphysema. In: Davis GS, editor. Medical management of pulmonary diseases. New York (NY): Marcel Dekker Inc, 1999: 451-74
9. Palm KH, Decker WW. Acute exacerbations of chronic obstructive pulmonary disease. Emerg Med Clin North Am 2003 May; 21 (2): 331-52
10. Lee-Chiong Jr TL, Matthay RA. COPD and the left heart. In: Similowski TS, Whitelaw WA, Derenne J-P, editors. Clinical management of chronic obstructive pulmonary disease. New York (NY): Marcel Dekker Inc, 2002: 533-48
11. Sweetman SC, editor. Martindale: the complete drug reference. 34th ed. London: Pharmaceutical Press, 2005
12. Barnes PJ. Autonomic pharmacology of the airways. In: Chung KF, Barnes PJ, editors. Pharmacology of the respiratory tract: experimental and clinical research. New York (NY): Marcel Dekker Inc, 1993: 415-456
13. Eisai Co Ltd. Aricept prescribing information 2002 [online]. Available from URL: http://www.aricept.com/pi/aricept_pi.htm [Accessed 2004 May 12]
14. Novartis Pharmaceuticals Corporation. Exelon prescribing information 2001 [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/ exelon.pdf [Accessed 2004 May 17]
15. Ortho-McNeil Neurologics, Inc. Razadyne Prescribing Information 2005 [online]. Available from URL: http://www.razadyne.com/active/janus/en_US/assets/ common/company/pi/razadyne.pdf [Accessed 2005 Nov 8]
16. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998 May; 158 (9): 1021-31
17. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998 Jan; 50 (1): 136-45
18. Relkin NR, Reichman WE, Orazem J, et al. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 2003; 16 (1): 18-24
19. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999 Mar; 318 (7184): 633-8
20. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 55-65
21. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000 Jun; 54 (12): 2261-8
22. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000 Jun; 54 (12): 2269-76
23. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000 Dec; 321 (7274): 1445-9
24. Lyketsos CG, Reichman WE, Kershaw P, et al. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry 2004 Sep-Oct; 12 (5): 473-82
25. Frolich L, Klinger T, Berger FM. Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease. J Neurol Sci 2002 Nov; 203-204: 137-9
26. Schmidt R, Lechner A, Petrovic K. Rivastigmine in outpatient services: experience of 114 neurologists in Austria. Int Clin Psychopharmacol 2002 Mar; 17 (2): 81-5
27. Aguglia E, Onor ML, Saina M, et al. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004 Nov; 20 (11): 1747-52
28. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000 May; 117 (5 Suppl. 2): 398S-401S
29. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21 Suppl. 41: 46S-53S
30. Petri H, de Vet HC, Naus J, et al. Prescription sequence analysis: a new and fast method for assessing certain adverse reactions of prescription drugs in large populations. Stat Med 1988 Nov; 7 (11): 1171-5
31. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996 Sep; 7 (5): 478-84
32. Petri H, Leufkens H, Naus J, et al. Rapid method for estimating the risk of acutely controversial side effects of prescription drugs. J Clin Epidemiol 1990; 43 (5): 433-9
33. van Dijk KN, de Vries CS, van den Berg PB, et al. Constipation as an adverse effect of drug use in nursing home patients: an overestimated risk. Br J Clin Pharmacol 1998 Sep; 46 (3): 255-61
34. Bytzer P, Hallas J. Drug-induced symptoms of functional dyspepsia and nausea: a symmetry analysis of one million prescriptions. Aliment Pharmacol Ther 2000 Nov; 14 (11): 1479-84
35. Movig KL, Leufkens HG, Belitser SV, et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 2002 Jun; 11 (4): 271-9
36. Hersom K, Neary MP, Levaux HP, et al. Isotretinoin and antidepressant pharmacotherapy: a prescription sequence symmetry analysis. J Am Acad Dermatol 2003 Sep; 49 (3): 424-32
37. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York (NY): John Wiley & Sons Inc, 2000
38. The Joint National Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997 Nov; 157 (21): 2413-46
39. Craig T, Richerson HB, Moeckli J. Problem drugs for patients with asthma. Compr Ther 1996 Jun; 22 (6): 339-44
40. O'Malley K, Cox JP, O'Brien E. Choice of drug treatment for elderly hypertensive patients. Am J Med 1991 Mar; 90 Suppl. 3A: 27S-33S
41. White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease 6: the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003 Jan; 58 (1): 73-80
42. Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health 2000; 21: 193-221